Shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) took a 14 percent bounce early Monday after the Tel Aviv, Israel-based company reported that the first phase III study of RHB-104 to test its hypothesis on Mycobacterium avium paratuberculosis (MAP) infection in Crohn's disease met its primary and key secondary endpoints. But those gains eroded, with shares closing at $8.75 for a loss of 68 cents, or 7.2 percent, after unanswered questions about the data, which remain under analysis, and the design of a follow-on phase III that company officials deemed likely once they have a chance to meet with the FDA.